AbbVie announced new positive data from its Phase 3 AFFIRM study for SKYRIZI in Crohn's disease, showing significant rates of endoscopic remission and ulcer-free endoscopy. This data reinforces SKYRIZI's efficacy and potential as an induction treatment, strengthening AbbVie's position in the inflammatory bowel disease market.
AbbVie released new, detailed efficacy results from its Phase 3 AFFIRM study for SKYRIZI in Crohn's disease, presented at a scientific meeting. The key finding is that 35.8% of patients achieved endoscopic remission, with even higher rates in advanced therapy-naïve patients. This positive data strengthens SKYRIZI's market position and competitive profile against other treatments for Crohn's disease. For traders, this is a positive signal for ABBV's drug pipeline and future revenue potential, potentially leading to a modest short-term uplift and long-term confidence in the drug's market share. The main opportunity is for ABBV to further solidify its leadership in immunology.